Solostar Injection Pen Approved for Diabetes

THURSDAY, Feb. 26 (HealthDay News) -- Sanofi-Aventis's Apidra (insulin glulisine) Solostar injection pen has been approved to treat diabetes, the company said Thursday in a news release.

The disposable pen with rapid-acting insulin was approved for adults with type 2 diabetes and for children four years and older with type 1 diabetes.

The device requires lower injection force than competing products, the drug maker said.

More information

The FDA has additional information about Apidra, a drug first approved in 2004.